The Europe Lung Cancer Therapeutics Market was worth USD 1.67 billion in 2020 and estimated to be growing at a CAGR of 6.47%, to reach USD 2.29 billion by 2025. Europe is the second-largest region for the lung cancer therapeutics market.
Lung cancer is the foremost cause of cancer deaths in the European region, and the prevalence of lung cancer is cumulative significantly. It is the common cause of mortality and illness not only in developed countries but also in developing countries. Smoking is thought of as the main cause of lung cancer, though lung cancer also follows in non-smokers.
Growth in the lung cancer therapeutics market is projected on account of growing prevalence rate, constant contact to radiation and carcinogens and increasing patient alertness.
Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment, and thus makes higher revenues for the Europe treatment market.
This research report on the Europe Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:
By Treatment Type:
By Country:
Regionally, U.K is the leading market due to a high population base suffering from lung cancer while Germany is anticipated to witness high growth in the forecast period.
Key players operating in the Europe Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Cisplatin
5.1.1.2 Taxol
5.1.1.3 Navelbine
5.1.1.4 Camptosar
5.1.1.5 Alimta
5.1.2 Radiotherapy
5.1.2.1 External Beam
5.1.2.2 Internal Beam
5.1.2.3 Systemic
5.1.3 Other Drugs
5.1.3.1 Abraxane
5.1.3.2 Avastin
5.1.3.3 Crizotinib
5.1.3.4 Docetaxel
5.1.3.5 Gefitinib
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 BoehringerIngelheim GmbH
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Hoffman-La Roche
8.3 Pfizer Inc.
8.4 GlaxoSmitKline
8.5 Eli Lilly and Company
8.6 AstrazenecaPlc
8.7 Sanofi-Aventis
8.8 Agennix AG
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports